Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation

1. The panel recommends post–autologous HCT consolidation/maintenance with BV for 16 cycles in BV-naïve classic Hodgkin lymphoma (HL) with at least 1 or more high-risk features as defined by the AETHERA study.^a ( A )

2. The panel does not recommend postautologous HCT consolidation/ maintenance with BV for HL with prior evidence of disease refractory to BV. ( C )

3. The recommended duration of post–auto-HCT BV consolidation/maintenance therapy is for a maximum of 16 cycles every 3 weeks as described in AETHERA trial, or until unacceptable toxicity or disease relapse/progression (whichever occurs first).^a ( A )

4. The panel recommends post–autologous HCT consolidation/ maintenance with BV in HL with one or more high-risk features as defined by the AETHERA trial and limited prior exposure to BV (approximately 4-6 cycles) preceding the autologous HCT, but without any evidence of BV refractory disease. ( C )

5. Sufficient data do not exist to use the preautologous-HCT PET (or PET/CT) scan status to guide the use of post–autologous HCT consolidation/maintenance therapy with BV for HL with one or more high-risk features as defined by AETHERA Trial. ( C )